A qualitative examination of the indirect effects of modified directly observed therapy on health behaviors other than adherence

AIDS Patient Care and STDs

Volumn 22, Issue 8, 2008, Pages 663-668

  Bradley Ewing, Andrea ^a   Thomson, Domonique ^a   Pinkston, Megan ^a   Goggin, Kathy J ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; ATTITUDE TO HEALTH; DAILY LIFE ACTIVITY; DEMOGRAPHY; DIRECTLY OBSERVED THERAPY; FEMALE; HEALTH BEHAVIOR; HEALTH CARE PERSONNEL; HUMAN; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; MODIFIED DIRECTLY OBSERVED THERAPY; PATIENT COMPLIANCE; PATIENT SATISFACTION; QUALITATIVE ANALYSIS;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BEHAVIOR THERAPY; DIRECTLY OBSERVED THERAPY; FEMALE; HEALTH BEHAVIOR; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; QUESTIONNAIRES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 50149115236     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2007.0190     Document Type: Article

References (39)

1. Detels R, Munoz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration AIDS. JAMA 1998;280:1497-1503.
2. Jensen-Fangel A, Pederson L, Pederson C, et al. Low mortality in HIV-infected patients starting highly active antiretroviral therapy: A comparison with the general population. AIDS 2004;18:89-97.
3. Palella FJ, Deloria-Knoll M, Chimiel JS, et al. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann Intern Med 2003;138:620-626.
4. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-860.
5. Shor-Posner G, Lecusay R, Miguez-Burbano MJ, et al. Quality of life measures in the Miami HIV-1 infected drug users cohort: Relationship to gender and disease status. J Subst Abuse 2000;11:395-404.
6. Whitman S, Murphy J, Cohen M, Sherer R. Marked declines in human immunodeficiency virus-related mortality in Chicago in women, African Americans, Hispanics, young adults, and injection drug users from 1995 through 1997. Arch Intern Med 2000;160:365-369.
7. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and Outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30.
8. Bangsberg D. Less than 95% adherence to nonnucleoside reverse transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis 2006;43:939-941.
9. Maggiolo F, Ravasio L, Ripamonti D, et al. Similar adherence rates favor different virologic outcomes for patients treated with nonnucloeside analogues or protease inhibitors. Clin Infect Dis 2005;40:158-163
10. Read T, Mijch A, Fairley CK. Adherence to antiretroviral therapy: Are we doing enough? Intern Med J 2003;33:254-256.
11. Johnson MO, Catz SL, Remien RH, et al. Theory-guided, empirically supported avenues for intervention on HIV medication nonadherence: Findings from the healthy living project. AIDS Patient Care STDs 2003;17:645-656.
12. Altice FL, Friedland GH. The era of adherence to HIV therapy. Ann Intern Med 1998;129:503-504.
13. Bartlett JA. Addressing the challenges of adherence. J Acquir Immune Defic Syndr 2002;29:S2-10.
14. Halkitis PN, Parsons JT, Wolitski RJ, Remien RH. Characteristics of HIV antiretroviral treatments, access and adherence in an ethnically diverse sample of men who have sex with men. AIDS Care 2003;15:89-102.
15. Singh N, Squier C, Sivek C, Wagener M. Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: Prospective assessment with implications for enhancing compliance. AIDS Care 1996;8:261-269.
16. Weidle PJ, Ganea, CE, Irwin KL, et al. Adherence to antiretroviral medications in an inner-city population. J Acquir Immune Defic Syndr 1999;22:498-502.
17. Chesney MA. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis 2000;30:S171-176.
18. Remien RH, Hirky AE, Johnson MO, Weinhardt LS, Whittier D, Le GM. Adherence to medication treatment: A qualitative study of facilitators and barriers among a diverse sample of HIV+ men and women in four U.S. cities. AIDS Behav 2003;7:61-72.
19. Babudieri S, Aceti A, D'Offizi GP, Carbonara S, Starnini G. Directly observed therapy to treat HIV infection in prisoners. JAMA 2000;284:179-180.
20. Lanzafame M, Trevenzoli M, Cattelan AM, Rovere P, Parrinello A. Directly observed therapy in HIV therapy: a realistic perspective? J Acquir Immune Defic Syndr 2000;25:200-201.
21. st International Conference on HIV Treatment Adherence (IAPAC). Jersey City, NJ: March 2006.
22. Bednall R, Dean G, Bateman N. Directly observed therapy for the treatment of tuberculosis - Evidence based dosage guidelines. Respir Med 1999;93:759-762.
23. Chaulk CP, Kazandijan VA. Directly observed therapy for the treatment completion of tuberculosis. Consensus statement of the public health tuberculosis guidelines panel. JAMA 1998;279:943-948.
24. Jayaweera DT, Kolber MA, Brill M, et al. Effectiveness and tolerability of a once-daily amprenavir/ritonavir-containing highly active antiretroviral therapy regimen in antiretroviral-naïve patients at risk for nonadherence: 48-week results after 24 weeks of directly observed therapy. HIV Med 2004;5:364-370.
25. White BL, Wohl DA, Hays RD, et al. A pilot study of health beliefs and attitudes concerning measures of antiretroviral adherence among prisoners receiving directly observed antiretroviral therapy. AIDS Patient Care STDs 2006;20:408-417.
26. Stenzel MS, McKenzie M, Mitty JA, Flanigan TP. Enhancing adherence to highly active antiretroviral therapy (HAART): A pilot program of modified directly observed therapy (MDOT). AIDS Read 2001;11:317-328.
27. Lucas GM, Flexner CW, Moore RD. Directly administered antiretroviral therapy in the treatment of HIV infection: Benefit or burden? AIDS Patient Care STDs 2002;16:527-535.
28. Behforouz HL, Farmer PE, Mukherjee JS. From directly observed therapy to accompagnateurs: Enhancing AIDS treatment outcomes in Haiti and in Boston. Clin Infect Dis 2004;38:S429-436.
29. Wohl AR, Garland WH, Squires K, et al. The feasibility of a community-based directly administered antiretroviral therapy program. Clin Infect Dis 2004;38:S388-392.
30. Mitty JA, Macalino G, Bazerman LB, et al. The use of community-based modified directly observed therapy for the treatment of HIV-infected persons. J Acquir Immune Defic Syndr 2005;39:545-550.
31. Lucas GM, Mullen BA, McCaul ME, Weidle PJ, Hader S, Moore RD. Adherence, drug use, and treatment failure in a methadone clinic-based program of directly administered antiretroviral therapy. AIDS Patient Care STDs 2007;21:564-574.
32. Goggin K, Liston RJ, Mitty JA. Modified directly observed therapy for antiretroviral therapy: A primer for the field. Public Health Rep 2007;122:472-481.
33. Goicoechea M, Best B, Seefried E, Wagner G, Capparelli E, Haubrich R. Failure of modified directly observed therapy combined with therapeutic drug monitoring to enhance antiretroviral adherence in a patient with major depression. AIDS Patient Care STDs 2006;20:233-237.
34. Fisher JD, Fisher WA. The information-motivation-behavioral skills model. Emerging theories in health promotion practice and research. DiClemente R, Crosby R, Kegler M (eds). San Francisco, CA: Jossey Bass, 2002:40-70.
35. Fisher JD, Fisher WA, Amico KR, Harman JJ. An information-motivation- behavioral skills model of adherence to antiretroviral therapy. Health Psychol 2006;25:462-473.
36. Mitty JA, Macalino G, Taylor L, Harwell JI, Flanigan TP. Directly observed therapy (DOT) for individuals with HIV: Successes and challenges. MedGenMed 2003;5:30.
37. Gerkovich MM, Goggin KJ, Wright J, et al. Design and implementation of a multi-modal adherence trial. Presented at the Enhancing Adherence: A State of the Science Meeting on Intervention Research to Improve Anti-Retroviral Adherence, New Haven, CT: 2005
38. Volmink J, Garner P. Directly observed therapy for treating tuberculosis. Cochrane Database Syst Rev 2006;2:CD003343
39. Goldie SJ, Paltiel AD, Weinstein MC, et al. Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. Am J Med 2003;115:632-641.